CHFR and ovarian cancer: In contrast to their report, the present study directly examined the expression of CHFR rather than a CHFR regulatory protein, specified the “paclitaxel-containing therapy” patients received (see Methods), and performed subgroup analysis that focused on HGSOC, the most common subtype of ovarian cancer treated with paclitaxel.